Trial Profile
Omalizumab in children with seasonal allergic rhinitis also receiving either birch pollen allergy immunotherapy or grass pollen allergy immunotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary) ; Birch pollen allergy immunotherapy; Grass pollen allergy immunotherapy
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 05 Nov 2010 New trial record.